Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression

Jabbour E, Duell J, Yilmaz M, Khoury JD, Ravandi F, Jain N, Einsele H, Garcia-Manero G, Konopleva M, Short NJ, Thompson PA, Wierda W, Daver N, Cortes J, O'Brien S, Kantarjian H, Topp MS (2018)

Publication Type: Journal article

Publication year: 2018

Journal

American Journal of Hematology Wiley-Blackwell

Book Volume: 93

Pages Range: 371-374

Journal Issue: 3

DOI: 10.1002/ajh.24987

Abstract

Blinatumomab, a bi-specific T-cell engaging CD3-CD19 antibody construct, has shown significant activity in patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (ALL). Despite this improvement, most patients relapse. Here, we describe the outcome of 68 patients with R/R ALL after failure of blinatumomab therapy: 38 (56%) blinatumomab refractory; 30 (44%) relapsing after initial response. After a median follow-up of 49 months, 9 (13%) patients remained alive. The median overall survival after blinatumomab failure was 5.2 months. At the time of failure, among 61 patients evaluated for immunophenotype, 56 (92%) had CD19-positive blasts; only five (8%) had ALL recurrence with CD19-negative disease. Two patients progressed with lower CD19 expression. In summary, the outcome of patients with R/R ALL after blinatumomab failure is poor and treatment of these patients remains an unmet medical need. Our findings indicate that blinatumomab therapy would not exclude a significant number of patients from the potential benefit of subsequent CD19-directed therapies such as chimeric antigen receptor T-cell therapy.

Involved external institutions

University of Texas MD Anderson Cancer Center US United States (USA) (US) University of California Irvine US United States (USA) (US) Universitätsklinikum Würzburg DE Germany (DE)

How to cite

APA:

Jabbour, E., Duell, J., Yilmaz, M., Khoury, J.D., Ravandi, F., Jain, N.,... Topp, M.S. (2018). Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression. American Journal of Hematology, 93(3), 371-374. https://doi.org/10.1002/ajh.24987

MLA:

Jabbour, Elias, et al. "Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression." American Journal of Hematology 93.3 (2018): 371-374.

BibTeX: Download